Detalhe da pesquisa
1.
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.
N Engl J Med
; 384(12): 1089-1100, 2021 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33761206
2.
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.
N Engl J Med
; 384(11): 1003-1014, 2021 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730454
3.
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
PLoS Med
; 17(2): e1003038, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32092060
4.
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.
J Infect Dis
; 215(9): 1376-1385, 2017 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28199679
5.
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.
N Engl J Med
; 369(22): 2083-92, 2013 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-24099601
6.
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Lancet HIV
; 5(7): e366-e378, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29898870
7.
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.
Stat Commun Infect Dis
; 9(1)2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29218117
8.
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.
PLoS One
; 10(9): e0137666, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26368824